This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pharmagen To Present Strategic Vision For Solving Nation's Parenteral Drug Shortage Crisis At 2013 BIO International Convention

SILVER SPRING, Md., April 22, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen") is excited to announce that it will present its strategic vision for solving the Nation's parenteral drug shortage crisis at the 2013 Biotechnology Industry Organization (BIO) International Convention held in Chicago, Illinois on April 23, 2013. The presentation will be given at the North Carolina Pavilion, Booth #2617, at 4:00 pm local time.

Pharmagen, in conjunction with biopharmaceutical industry leaders BioPlan Associates and Kymanox, will release the results of a comprehensive market analysis of the Nation's parenteral drug shortage crisis and outline a revolutionary supply chain and production methodology to address the problem. BioPlan Associates has identified that shortages cost US health providers well over $216 million annually in extra labor to simply manage; these shortages also pose serious risks to successful and expedient patient outcomes. The concern for patient safety is at the forefront of health policy after the 2012 Meningitis Outbreak and the Food & Drug Administration (FDA) has been looking for solutions to combat the shortage epidemic. Supply issues are expected to continue and Pharmagen estimates that the total market opportunity approaches $1 billion as US baby boomers are aging. Kymanox, a specialty process engineering and regulatory compliance company, has bundled a suite of new production methodologies that will allow Pharmagen to leverage its proprietary knowledge of drug shortages and translate it into cGMP, FDA-approved products that will fill critical supply gaps. This novel approach – coupled with a newly coined concept known as cGMP +® – will allow Pharmagen to produce the highest quality sterile injectables on the market today.

"We've spent the last 6 months studying this issue with some of the brightest minds in the pharmaceutical business. The buy-in from our partners and the enthusiastic encouragement from our customers is validation that there's an enormous opportunity here. Our plan is predicated on a bottom-up approach that allows us to leverage our intricate knowledge of the shortage market with an FDA-approved facility that can turn out finished drugs in a matter of days, not months. Our ability to connect a dynamic market with what's been traditionally a slow manufacturing ecosystem is what makes us special. Given this positioning, there isn't another company out there that can do what we do," said Mackie A. Barch, CEO of Pharmagen.

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions.  Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.

About Kymanox

Kymanox, with headquarters now in RTP, North Carolina, is a premier technical products and technical project management company. We have expertise in providing engineering, scientific, and regulatory support to companies involved in Biopharmaceutical, Medical Device, and Nanotechnology development. Kymanox has a proven track record in solving complex scale-up, technology transfer, and manufacturing problems – as well as receiving positive feedback from the FDA on executing complex approval pathways for next generation drugs.  With our focus on commercialization, Kymanox helps bring new products to patients in need.

About BioPlan Associates

BioPlan Associates is a strategic marketing and marker research consultancy, providing analysis to biotech and pharma companies for over 20 years. BioPlan helps their clients understand market and customers' needs. This is especially important in fast-moving biotechnology, life sciences, and health sciences markets. They Deliver confidence. Their clients' decisions are based on customer needs. Their technology clients get the decision-making tools and actionable information they need to make decisions  today.  BioPlan supports biopharmaceutical, biotech, diagnostics, and life sciences suppliers seeking customer needs analysis need to make smart decisions.

Contact:  888-264-4597 or info@pharmagenrx.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,159.93 +128.79 0.76%
S&P 500 2,001.17 +17.04 0.86%
NASDAQ 4,550.9590 +32.0570 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs